Column Group L P's Form 4 filing
NGM Biopharmaceuticals Inc (NGM) · filed Jun 13, 2022
- Accession no.
- 0000899243-22-022214
- Filed
- Jun 13, 2022, 5:05 PM ET
- Trade date
- Jun 9, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $13.3M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Column Group L PCIK 0001347769 | Director, 10% Owner |
| Column Group GP, LPCIK 0001614627 | 10% Owner |
| Column Group III-A, LPCIK 0001668085 | 10% Owner |
| Column Group III, LPCIK 0001668159 | 10% Owner |
| Column Group IV-A, LPCIK 0001796353 | 10% Owner |
| Column Group IV, LPCIK 0001796354 | 10% Owner |
| Column Group IV GP, LPCIK 0001796356 | 10% Owner |
| TCG IV GP, LLCCIK 0001796359 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 9, 2022 | Common Stock | PPurchaseAcquired | +951,684 | $13.50 | +$12,847,734 | 2,650,177 | Indirect | Duplicate filing |
| Jun 9, 2022 | Common Stock | PPurchaseAcquired | +32,477 | $13.50 | +$438,439.5 | 90,442 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Due to SEC restrictions on the number of reporting owners, this is Form 2 of 2.